Literature DB >> 20386777

Unusual scarring patterns on cardiac magnetic resonance imaging: A potentially treatable etiology not to be missed.

Andrew Jordan1, Jonathan Lyne, Tom Wong.   

Abstract

A case of cardiomyopathy and ventricular tachycardia previously assumed to be idiopathic in origin is described. Investigation with cardiac magnetic resonance imaging prompted the diagnosis and successful treatment of an underlying disorder based on typical scarring patterns seen with late gadolinium enhancement. The present report suggests that clinicians should have a low threshold for actively excluding this condition in patients presenting with cardiomyopathy, even in the absence of other disease features, particularly if typical scarring patterns are found on cardiac magnetic resonance imaging because disease-specific therapy appears to significantly improve both symptoms and prognosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20386777      PMCID: PMC2886540          DOI: 10.1016/s0828-282x(10)70374-3

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  5 in total

Review 1.  Cardiac magnetic resonance in myocardial disease.

Authors:  U Sechtem; H Mahrholdt; H Vogelsberg
Journal:  Heart       Date:  2006-06-06       Impact factor: 5.994

2.  Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy.

Authors:  B Sachdev; T Takenaka; H Teraguchi; C Tei; P Lee; W J McKenna; P M Elliott
Journal:  Circulation       Date:  2002-03-26       Impact factor: 29.690

3.  High incidence of later-onset fabry disease revealed by newborn screening.

Authors:  Marco Spada; Severo Pagliardini; Makiko Yasuda; Turgut Tukel; Geetha Thiagarajan; Hitoshi Sakuraba; Alberto Ponzone; Robert J Desnick
Journal:  Am J Hum Genet       Date:  2006-04-28       Impact factor: 11.025

4.  Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.

Authors:  D A Hughes; P M Elliott; J Shah; J Zuckerman; G Coghlan; J Brookes; A B Mehta
Journal:  Heart       Date:  2007-05-04       Impact factor: 5.994

5.  Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.

Authors:  A Mehta; R Ricci; U Widmer; F Dehout; A Garcia de Lorenzo; C Kampmann; A Linhart; G Sunder-Plassmann; M Ries; M Beck
Journal:  Eur J Clin Invest       Date:  2004-03       Impact factor: 4.686

  5 in total
  1 in total

1.  Sarcospan Regulates Cardiac Isoproterenol Response and Prevents Duchenne Muscular Dystrophy-Associated Cardiomyopathy.

Authors:  Michelle S Parvatiyar; Jamie L Marshall; Reginald T Nguyen; Maria C Jordan; Vanitra A Richardson; Kenneth P Roos; Rachelle H Crosbie-Watson
Journal:  J Am Heart Assoc       Date:  2015-12-23       Impact factor: 5.501

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.